Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kodiak Sciences Inc - Common Stock (NQ:KOD)

42.20 -1.06 (-2.45%)
Streaming Delayed Price Updated: 3:42 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kodiak Sciences Inc - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know ↗
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline. 
Via The Motley Fool
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
News headline image
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action? ↗
Kodiak Sciences Inc (NASDAQ: KOD) shares are trading higher Friday after positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy. 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study.... 
Via MarketMinute
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy ↗
Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
This Coinbase Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Top stock movements in today's session. ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock ↗
Kodiak Sciences posted a second-quarter loss of $1.03 per share, compared to market estimates of a loss of $1.02 per share. 
Via Benzinga
News headline image
Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Kodiak Sciences Beats Q2 Loss Estimates ↗
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.